Gynecological and sexual health after radiotherapy for anal cancer.
Official title: DACG VI. Beyond Survival: Addressing Gynecological and Sexual Health in Women After Radiotherapy for Anal Cancer
Run by Aarhus University Hospital · NCT07296237 · Data updated 2026-11-12
See if vaginal problems and changes in sexual health are linked to radiation dose in women treated with chemoradiotherapy for anal cancer 6–36 months after treatment.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 18 Years and up |
| Sex | Women only |
| Enrollment | 80 (estimated) |
| Sponsor | Aarhus University Hospital Academic / other |
| Drugs / interventions | chemotherapy, radiation |
| Locations | 3 sites (Aarhus and 2 other locations) |
| Status | Recruiting |
| Started | November 13, 2025 |
| Main results expected | September 1, 2026 |
| Study ends | September 1, 2026 |
| Registry record updated | December 22, 2025 |
| Trial ID | NCT07296237 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Women aged 18 or older in Denmark who were treated with curative chemoradiotherapy for anal cancer, are 6–36 months post‑radiotherapy, can give written consent, and can complete Danish questionnaires.
✕Probably not a fit
People unlikely to benefit include those who had prior pelvic radiotherapy, received electron beam radiotherapy, are outside the 6–36 month window, cannot speak Danish, or are not women treated for anal cancer.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This observational study follows women treated with curative chemoradiotherapy for anal cancer to document vaginal and sexual changes 6–36 months after radiotherapy. Participants complete online quality-of-life and sexual health questionnaires and undergo a gynecological exam to check for narrowing, stiffness, bleeding, or scarring. The study links clinical findings to recorded radiation doses to the vagina to explore dose–response relationships. It also collects information on supportive care received and patient satisfaction with that care.
Why it matters
Potential benefit: If successful, the findings could help clinicians prevent or better manage vaginal and sexual side effects by informing follow-up care, patient counseling, and possible dose-planning limits.
How similar studies have gone: Previous observational work using exams and patient‑reported questionnaires has documented pelvic radiation effects in gynecologic and rectal cancer, but focused data specifically on vaginal outcomes after anal cancer radiotherapy remain limited.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Women aged 18 years or older * Diagnosed with anal cancer * Treated with chemoradiotherapy with curative intent * Between 6 and 36 months since completion of radiotherapy * Able and willing to give written informed consent Exclusion Criteria: * Previous pelvic radiotherapy for another disease * Treated with electron beam radiotherapy * Unable to speak or understand Danish
Where it's running
-
Department of Oncology Aarhus University Hospital (AUH)
Aarhus, Denmark Recruiting -
Department of Oncology, Herlev and Gentofte Hospital
Herlev, Denmark Recruiting -
Department of Oncology Vejle Hospital, University Hospital of Southern Denmark
Vejle, Denmark Recruiting
Study contacts
- Study coordinator: Johanne H. Steffensen, MD.
- Email: johste@oncology.au.dk
- Phone: 004551434830
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Retifanlimab after chemoradiation for anal cancer
This study tests whether retifanlimab can help people with anal squamous cell carcinoma who have completed chemoradiation and still have residual disease.
-
Irreversible Electroporation for Recurrent Pelvic Tumors
This study tests whether using irreversible electroporation (IRE) is safe and helps control recurrent pelvic tumors in adults who can’t have other local treatments.
-
HPV DNA-guided chemoradiation with Retifanlimab for locally advanced anal cancer
This study tests whether adjusting chemoradiation doses based on HPV ctDNA results and adding Retifanlimab after CRT can improve outcomes for adults with new, locally advanced anal cancer.
-
Self-sampling to improve anal lesion outcomes
This study will test whether people at higher risk for anal cancer will use a self-collected anal swab and whether that increases follow-up cytology and high-resolution anoscopy (HRA) appointment attendance.
-
Testing trastuzumab deruxtecan (T‑DxD) for HER2‑positive advanced solid tumors
This will test whether trastuzumab deruxtecan (T‑DxD) helps adults in the US with HER2‑positive (IHC 3+) locally advanced, unresectable, or metastatic solid tumors who have had prior systemic treatment and have no satisfactory alternative options.
-
Virtual exercise program to preserve function and prevent disability during chemotherapy
This trial tests whether supervised resistance sessions by video plus short home aerobic workouts help adults 18–64 maintain strength and stay active while receiving curative-intent chemotherapy.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.